"Z944. Received a key U.S. patent issued in February 2013 providing broad patent coverage for Z944, a novel, oral, T-type calcium channel blocker, through April 2029. Z944 completed Phase 1 single and multiple ascending dose clinical studies in late 2012 and the Company plans to continue further clinical development with Z944 during 2013."
I'm wondering if during the MAD, they found other indications? The FL connection, patent coverage, etc and are just trying to figure out which way to take it (revenue vs trial cost). Find an easy bar to get over that can fund further indications... or liciense it out for A and B.for cash.. keep C and D in house as a cow. We will know when they decide it is time to shine the light on us mushrooms.
i'd have to agree something was definitely triggered during the MAD study .. time will tell ... im just ticked about them not meeting the 1st quarter 2013 deadline as mentioned in previous PRs.. better be worth the wait
how about a close above .68 with some afternoon volume kicking in, that would get things going.. i can dream, right haha